FDA expands Winrevair’s label with HYPERION data, formalizes the use of non-animal testing methods, and Amgen reports positive Phase 3 results for dazodalibep in Sjögren disease.
|Articles|July 8, 2022
Early Detection of Aggregation in Formulations: FlowCam Nano for submicron particle characterization in biotherapeutics
Author(s)Yokogawa Fluid Imaging Technologies
In this white paper, we demonstrate the analysis capabilities of FlowCam Nano for biotherapeutic formulation development. This study compares the results from FlowCam Nano with those from FlowCam 8100 when analyzing samples containing protein aggregates, sucrose particles, and bacteria. We also demonstrate the consistency of the particle concentration measurements with FlowCam Nano and how the instrument may also be used to determine relative particle concentrations in samples.
Related to this article
The FDA has approved a label update for Merck's Winrevair (sotatercept-csrk) incorporating Phase 3 HYPERION data, showing a 76% reduction in clinical worsening events when added to background therapy in adults diagnosed with pulmonary arterial hypertension within the past year.
BIIE CEO Dr Stephen Wilson outlines rapid growth plans and a multidisciplinary technology stack targeting global clinical translation.
FDA's new rule formally recognizes non-animal methods like organoids and AI models as valid ways to support human drug testing.
Dazodalibep hit its phase 3 primary endpoint at week 48, building on phase 2 data showing a 6.3-point ESSDAI reduction versus placebo.
Glycomine's GLM101, an investigational liposomal mannose-1-phosphate substrate replacement therapy, has received FDA Breakthrough Therapy designation for PMM2-CDG, a rare glycosylation disorder with no approved treatments.
How early Phase I decisions can shape or compromise the regulatory and financing outcomes that define a biotech program's future.
Novo Nordisk reports positive phase 3 CagriSema data, Biocon’s pertuzumab biosimilar gets a positive CHMP opinion under EMA’s new tailored pathway, and Vironexis reports complete responses with its one-time in vivo therapy for relapsed ALL.